A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody
about
Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides.Applications of Replicating-Competent Reporter-Expressing Viruses in Diagnostic and Molecular VirologyImproved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyN-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formationIdentification of the HIV-1 gp41 core-binding motif--HXXNPF.The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41.Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesIn vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.Hendra and nipah infection: pathology, models and potential therapies.ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection.Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1.Respiratory syncytial virus entry inhibitors targeting the F protein.The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate.Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp413-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004-2010.Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocketSurface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core.Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry.Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation
P2860
Q24791794-7672A4C1-9298-4589-BB91-A458AEEF2F98Q24794033-C68944A7-64D4-48E6-AD9E-684EAA27B9D4Q26750838-6FDC6280-8043-451D-B998-7FAE742400B2Q30661709-2A972042-495C-4600-BE11-3FF0C997E3FAQ33208281-83C5EDDF-EE65-4A1A-B303-1274E304A36AQ33239507-0D5B8CBF-06AC-4D29-AD18-74FE72329C28Q33249271-14F48FF8-5415-49E6-B48F-D33C793C2992Q33253687-0AB22DA2-125E-4AAE-8BC3-93401154CF04Q33269255-6FC93D3E-F471-428D-A201-67237D26E3A3Q33429777-5BBC3751-33DA-4185-866C-A4DC5976CE99Q33622229-E9C4F14B-B9F0-472C-9D63-C06D22E3F6EBQ33826278-E88ADA52-08CB-462C-9519-0E83F01BDA3BQ33943822-1584E8D5-8169-4D8B-A895-C479CA5CF821Q33951142-D97C6099-AEFC-41C0-AB93-EAE7938D46D1Q33967511-BADD38BC-C4E3-4FEE-88BC-D1C0B2739A48Q34055847-1EEECB2A-5B0A-47D3-92CE-C2EF4F733180Q34536817-CA2647C5-1A40-47A2-85B0-0E93F5E3D7A4Q34761552-49F34373-8AF1-4AB4-912A-E50EDF8A197DQ35658146-BD352EAE-4FA9-416B-BEF1-4225732A8C55Q35960654-A84161A0-4AC9-4F74-BC57-1F1D6B801663Q36458359-40CBD69F-7167-4079-AB25-EE158B8FE66FQ36586879-3DBA689B-A17C-4E3C-B7A9-013C793D5D78Q36634815-807C4B81-417D-492D-9399-848196764CC3Q36643050-23929FFD-BF0A-484C-92C5-F5CD06A5C135Q36844408-A3A488EF-4D75-4E6D-BDA3-26D9887874BEQ36949390-BC4F2135-1C2E-48AF-AD91-FB35367424FAQ37130524-93046C3A-7719-4E4C-8381-D6A97F6057CAQ37258274-DCC5B08F-5549-4FA7-8C79-1BDC64AFAAB2Q37845842-2AB889EC-EF5F-4F45-AA46-A599BBBE566BQ38076321-7AF440E4-6792-4425-BF7A-F1DCFC278868Q39026284-FFDE5219-D16E-413F-A512-9967FE6A8A79Q39079796-1B7304F1-F2E3-4449-A3A2-4038D9F30CF7Q39597147-B6BB55EB-0A8F-4A09-A657-1F835BB18B31Q39732473-E5A1F46E-3AB2-45EA-AE93-CE7301824F59Q39766027-80AC2F2F-DA73-4B0A-954A-E77A7907FB17Q39794156-C7509D9F-50DF-4355-A6E3-DDBF505B947FQ39943795-BD6057C2-476C-4A49-9914-257F0FA6213DQ40298802-F9E60862-0053-4FA3-8ED9-004FAE25AB56Q40510097-152A825F-2077-4E25-882C-CF458C6AC2A6Q42180923-43E75EC8-6E19-4C3B-B810-E7540960CC17
P2860
A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A screening assay for antivira ...... n-specific monoclonal antibody
@ast
A screening assay for antivira ...... n-specific monoclonal antibody
@en
A screening assay for antivira ...... n-specific monoclonal antibody
@nl
type
label
A screening assay for antivira ...... n-specific monoclonal antibody
@ast
A screening assay for antivira ...... n-specific monoclonal antibody
@en
A screening assay for antivira ...... n-specific monoclonal antibody
@nl
prefLabel
A screening assay for antivira ...... n-specific monoclonal antibody
@ast
A screening assay for antivira ...... n-specific monoclonal antibody
@en
A screening assay for antivira ...... n-specific monoclonal antibody
@nl
P2093
P3181
P1476
A screening assay for antivira ...... n-specific monoclonal antibody
@en
P2093
P3181
P356
10.1016/S0166-0934(99)00041-5
P407
P577
1999-06-01T00:00:00Z